文献速递神经免疫

多领域生活方式干预对多发性硬化患者的持续获益:LIMS研究24个月随访

Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis in the LIMS Study: A 24-Month Follow-Up.
PubMed 文献 · Neurology · 2026-09-24

本研究评估多发性硬化患者参加3个月多模式生活方式项目(地中海饮食、体力活动、睡眠与压力管理)后21个月维持期的长期效果。659名参与者中,MSIS-29身体和心理评分在干预期显著下降,24个月时相对基线仍改善或稳定;饮食依从性和体重指数改善最明显,体力活动依从性无显著变化。

要点

  • 3个月多模式生活方式干预后,MSIS-29身体和心理评分在24个月时相对基线仍改善或稳定。
  • 饮食依从性和体重指数改善最明显,干预期大幅改善且随访期部分维持。
  • 体力活动依从性无显著变化,患者报告结局的个体层面变化比例较小。

核心结论

  • 数字多模式生活方式干预与患者报告结局的 modest、主要为短期改善相关,并在饮食行为和身体成分上显示更明显的个体层面变化。
  • 这些发现支持生活方式干预在多发性硬化长期管理中的补充作用。

研究设计与样本

  • 多发性硬化患者参与3个月多模式生活方式项目(地中海饮食、体力活动、睡眠与压力管理),随后21个月维持期。
  • 共纳入659名参与者,平均年龄46岁(SD 11),84%为女性。
  • 患者报告结局在干预前3个月、基线、干预后及6、12、18、24个月评估,采用分段混合效应模型分析纵向变化,并计算超过最小可检测变化(SDC)的个体比例。

主要发现

  • 干预期MSIS-29身体和心理评分分别每月显著下降约0.8分和1.1分,长期随访中衰减。
  • 干预后MSIS-29身体和心理评分组内变化分别为-2.7(-3.7; -1.8)分和-3.7(-4.8; -1.6)分,第24个月分别为-0.8(-1.7; 0.3)分和-3.4(-4.6; -2.3)分,相对基线保持显著改善或稳定。
  • 仅约4%-7%的参与者超过MSIS-29的SDC。
  • 其他患者报告结局轨迹大致相似,短期 modest 改善后趋于稳定;饮食依从性和体重指数改善最明显,干预期大幅改善且随访期部分维持;体力活动依从性无显著变化。

临床怎么用

  • 多模式生活方式干预可作为多发性硬化长期管理的补充手段,尤其关注饮食行为和身体成分的改善。
  • 患者报告结局的改善主要为短期且个体层面变化比例有限,临床应合理设定期望。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) often leads to physical, cognitive, and psychological impairments substantially affecting daily functioning and quality of life. Because current disease-modifying therapies do not fully prevent disease progression, interest has grown in the potential role of modifiable lifestyle factors. We evaluated (1) whether effects on patient-reported outcomes were sustained up to 24 months and (2) long-term changes in lifestyle behaviors after completion of the lifestyle in MS program. METHODS: People with MS participated in a 3-month multimodal lifestyle program (i.e., Mediterranean-style diet, physical activity, and sleep and stress), followed by a 21-month maintenance phase. Patient-reported outcomes were assessed 3 months before the intervention, at baseline, postintervention, and after 6, 12, 18, and 24 months. The primary outcome was MS-related impact on daily functioning (MS Impact Scale-29 [MSIS-29]). Secondary outcomes included quality of life, general health, and MS-related symptoms. Longitudinal changes were analyzed using piecewise mixed-effects models, and individual-level change was evaluated using proportions exceeding the smallest detectable change (SDC). RESULTS: In total, 659 participants were included (mean age 46 years, SD 11; 84% female). During the intervention phase, MSIS-29 physical and psychological scores significantly decreased by approximately 0.8 and 1.1 points per month, respectively, followed by attenuation during long-term follow-up. This was reflected by within-group changes of -2.7 (-3.7; -1.8) and -3.7 (-4.8; -1.6) points after the intervention and -0.8 (-1.7; 0.3) and -3.4 (-4.6; -2.3) point at month 24, remaining significantly improved or stable relative to baseline. Only a small proportion of participants exceeded the SDC for MSIS-29 (approximately 4%-7%). Trajectories were broadly similar across other patient-reported outcomes, with modest short-term improvements and subsequent stabilization. Most pronounced effects were found for dietary adherence and body mass index, which improved substantially during the intervention and remained partially sustained during follow-up. No significant changes were observed in physical activity adherence. DISCUSSION: In this large, real-world study, a digital multimodal lifestyle intervention was associated with modest, mainly short-term improvements in patient-reported outcomes and more pronounced individual-level changes in dietary behavior and body composition. These findings support a complementary role for lifestyle interventions in long-term MS management. TRIAL REGISTRATION INFORMATION: The study was registered at ClinicalTrials.gov (Identifier: NCT05402501; classic.clinicaltrials.gov/ct2/show/NCT05402501).

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Gravesteijn AS, Nauta IM, Stob M, et al. Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis in the LIMS Study: A 24-Month Follow-Up. Neurology. 2026. PMID: 42784777. doi:10.1212/WNL.0000000000218542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。